- Home
- ESGL vs CNTX Comparison
ESGL vs CNTX Comparison
Compare ESGL & CNTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ESGL
- CNTX
- Stock Information
- Founded
- ESGL 1999
- CNTX 2015
- Country
- ESGL Singapore
- CNTX United States
- Employees
- ESGL 72
- CNTX N/A
- Industry
- ESGL
- CNTX Biotechnology: Pharmaceutical Preparations
- Sector
- ESGL
- CNTX Health Care
- Exchange
- ESGL Nasdaq
- CNTX Nasdaq
- Market Cap
- ESGL 99.1M
- CNTX 78.0M
- IPO Year
- ESGL N/A
- CNTX 2021
- Fundamental
- Price
- ESGL $2.30
- CNTX $0.69
- Analyst Decision
- ESGL
- CNTX Strong Buy
- Analyst Count
- ESGL 0
- CNTX 4
- Target Price
- ESGL N/A
- CNTX $6.00
- AVG Volume (30 Days)
- ESGL 35.3K
- CNTX 71.4K
- Earning Date
- ESGL 06-03-2025
- CNTX 05-07-2025
- Dividend Yield
- ESGL N/A
- CNTX N/A
- EPS Growth
- ESGL N/A
- CNTX N/A
- EPS
- ESGL N/A
- CNTX N/A
- Revenue
- ESGL $6,099,784.00
- CNTX N/A
- Revenue This Year
- ESGL N/A
- CNTX N/A
- Revenue Next Year
- ESGL N/A
- CNTX N/A
- P/E Ratio
- ESGL N/A
- CNTX N/A
- Revenue Growth
- ESGL N/A
- CNTX N/A
- 52 Week Low
- ESGL $0.86
- CNTX $0.55
- 52 Week High
- ESGL $3.00
- CNTX $2.75
- Technical
- Relative Strength Index (RSI)
- ESGL 61.13
- CNTX 38.57
- Support Level
- ESGL $1.71
- CNTX $0.66
- Resistance Level
- ESGL $2.43
- CNTX $0.79
- Average True Range (ATR)
- ESGL 0.19
- CNTX 0.07
- MACD
- ESGL 0.01
- CNTX -0.01
- Stochastic Oscillator
- ESGL 81.52
- CNTX 16.88
About ESGL ESGL Holdings Limited
ESGL Holdings Ltd is a waste management, treatment, and recycling company involved in the collection and recycling of hazardous and non-hazardous industrial waste from customers such as pharmaceutical, semiconductor, petrochemical, and electroplating companies.
About CNTX Context Therapeutics Inc.
Context Therapeutics Inc is a clinical-stage biopharmaceutical company advancing medicines for solid tumors. The development team is advancing a pipeline of various therapies with a primary focus on treating female, hormone-dependent cancer, including breast, ovarian, and endometrial cancer. The company's preclinical program, CTIM-76, is an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody (bsAb) that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6.